Researchers at Texas A&M University are exploring a novel approach to treating Alzheimer’s disease by utilizing nanoscale engineering. The project, led by neuroscientist Ashok K. Shetty and mechanical engineer Ya Wang, investigates how nanorobots delivered through a nasal spray could penetrate the blood-brain barrier.
The team aims to slow the progression of the neurodegenerative disease enough that patients might live out their natural lifespans before it significantly impacts them. This strategy focuses on functional management rather than elimination of the condition. Most Alzheimer’s patients are diagnosed in their late 70s or early 80s, and as life expectancy increases, slowing cognitive decline has become a primary research goal.
The project utilizes DDL-357, an experimental small-molecule drug that enhances levels of secreted clusterin. This protein helps prevent amyloid plaques from adhering to brain cells, similar to how cooking oil prevents food residue from sticking to pans. Previous studies have correlated DDL-357 with reduced inflammation in the brain.
Shetty noted that while historical drug development often centered on clearing amyloid-beta, scientific consensus now recognizes multiple cellular failures in Alzheimer’s. The team’s distinct approach targets several contributing factors to cognitive decline rather than focusing solely on plaque accumulation.
"Successfully slowing disease progression, even by 10 years, would have a massive impact on patients and their families," Shetty said.





